World’s First Wellness-Focused Psychedelic Therapy Trial Launches in Canada.
Community-funded study will evaluate whether therapist-guided psychedelic therapy can enhance everyday wellness
Victoria, BC, October 15, 2025 — A coalition of Canadian researchers, clinicians, and nonprofit advocates has received Health Canada authorization to launch PsilWell, the first clinical study designed to measure psychedelic-assisted group psychotherapy’s impact on overall wellness.
Sponsored by Hippo, the trial is led by grassroots nonprofit TheraPsil in partnership with SABI Mind Victoria, data-capture platform CRIO, and federally licensed supplier Filament Health, which is generously donating naturally-derived medicine for every session. Unlike pharmaceutical-backed studies, PsilWell is nanced entirely by participantfees and community donors, making volunteers direct stakeholders in the research.
“Hundreds of modern trials have examined psychedelics as potential treatments for conditions such as depression, PTSD, addiction and anxiety,”
“PsilWell now asks a different, equally important question: can the same therapy also cultivate greater overall wellness?”
Heesoo Cho, Co-Founder and Manaaging Director of SABI Mind, added:
“This trial marks an important step in expanding how we understand and support mental wellness. At SABI Mind, we’re honoured to help explore psychedelics’ potential not just for
healing, but for cultivating greater presence, purpose, and connection. With the right therapeutic container, we believe these experiences can be profoundly life-enhancing—and we’re proud to be part of a team brining this work forward with integrity, care, and vision.”
Participants will complete three weeks of preparatory group therapy, one supervised psychedelic therapy session, and three weeks of integration therapy with licensed clinicians trained through TheraPsil’s national program.
Adults aged 18–65 who meet medical safety criteria and can travel to Victoria may apply; the CAD 4,500 fee covers all screening, therapy, and follow-up. The coalition intends to open additional PsilWell sites in other Canadian cities, pending local partnerships and regulatory review.
Further details and an online interest form are available at therapsil.ca/clinical-trial, or by emailing PsilWell@HippoLifeScience.com.
Media contact
John Gilchrist - Director of Communications, TheraPsil
john@therapsil.ca | 647-505-3964
About TheraPsil
TheraPsil is a Canadian nonprofit advocating for legal, compassionate access to psychedelic-assisted psychotherapy for patients in medical need. Since 2020, TheraPsil has supported legal access for patients and trained over 800 healthcare professionals.
About SABI Mind
Based in Calgary and Victoria, SABI Mind supports the careful and necessary mending of mental health and chronic pain through psychedelic-assisted therapies. Founded by a group of Calgary-based entrepreneurs brought face-to-face with the challenges of those suffering from mental health conditions, SABI Mind empowers those discouraged by the conventional medicine methods with a patient-centred treatment model supported by experienced psychiatrists, anaesthesiologists, therapists, client experience specialists, and other clinic staff specially trained in psychedelic-assisted psychotherapy.
About CRIO
CRIO is a leading provider of eSource solutions for clinical research. The platform streamlines data collection and management, ensuring protocol compliance and reducing errors. By eliminating paper source and automating workflows, CRIO helps clinical trial sites and sponsors save time and money, improve data quality, and enhance patient safety. Our digital-first, site-centric approach makes clinical trials more efficient and effective. Learn more at clinicalresearch.io.
